Evidence map›Paper›PMID 27889185›Full record

ArticleCancer cell2016

NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis.

Haiming Xu, Daria G Valerio, Meghan E Eisold, Amit Sinha, Richard P Koche, Wenhuo Hu, Chun-Wei Chen, S Haihua Chu, Gerard L Brien, Christopher Y Park and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 163 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. RareAmerican journal of cancer research · 2026
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Haiming XuCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA. Electronic address: haiming_xu@dfci.harvard.edu.
Daria G ValerioCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Meghan E EisoldCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Amit SinhaCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Richard P KocheCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Wenhuo HuHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Chun-Wei ChenCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA.
S Haihua ChuCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Gerard L BrienCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Christopher Y ParkHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
James J HsiehHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Patricia ErnstDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Scott A ArmstrongCancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA. Electronic address: scott_armstrong@dfci.harvard.edu.
Memorial Sloan Kettering Cancer Center · USBoston Children's Hospital · USUniversity of Colorado Denver · US

Funding

TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5M
MLL Function in the Maintenance of the Blood Forming SystemR01HL090036 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ERNST, PATRICIA · 2007 to 2015
$3.8M
MLL Family Histone Methyltransferases in Myeloid LeukemiaR01CA224436 · NCI · UNIVERSITY OF COLORADO DENVER · PI ERNST, PATRICIA · 2018 to 2022
$2.1M
Molecular pathogenesis of MLL-AF4 leukemiasR01CA140575 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ARMSTRONG, SCOTT A · 2010 to 2014
$1.7M
Integrated Analyses of Taspase 1 (MLL Cleaving Protease)R01CA119008 · NCI · WASHINGTON UNIVERSITY · PI HSIEH, JAMES J · 2006 to 2010
$1.3M
Molecular Mechanisms of Impaired DAN Damage Response in Leukemia PathogenesisR01CA138505 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HSIEH, JAMES J · 2013 to 2015
$1.0M
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemiaR00CA197498 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, CHUN-WEI DAVID · 2017 to 2019
$747k
Molecular Mechanisms of Impaired DAN Damage Response in Leukemia PathogenesisU01CA138505 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HSIEH, JAMES J · 2011 to 2012
$746k
Genetic and Biochemical Analyses of MLL CleavageK01CA102594 · NCI · WASHINGTON UNIVERSITY · PI HSIEH, JAMES J-D · 2003 to 2007
$706k
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemiaK99CA197498 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, CHUN-WEI DAVID · 2016 to 2017
$308k
NCI NIH HHS K01 CA102594NCI NIH HHS K99 CA197498NCI NIH HHS P01 CA066996NCI NIH HHS R00 CA197498NCI NIH HHS R01 CA119008NCI NIH HHS R01 CA138505NCI NIH HHS R01 CA140575NCI NIH HHS R01 CA224436NCI NIH HHS U01 CA138505NHLBI NIH HHS R01 HL090036
6 · The paper itself

Abstract

The nucleoporin 98 gene (NUP98) is fused to a variety of partner genes in multiple hematopoietic malignancies. Here, we demonstrate that NUP98 fusion proteins, including NUP98-HOXA9 (NHA9), NUP98-HOXD13 (NHD13), NUP98-NSD1, NUP98-PHF23, and NUP98-TOP1 physically interact with mixed lineage leukemia 1 (MLL1) and the non-specific lethal (NSL) histone-modifying complexes. Chromatin immunoprecipitation sequencing illustrates that NHA9 and MLL1 co-localize on chromatin and are found associated with Hox gene promoter regions. Furthermore, MLL1 is required for the proliferation of NHA9 cells in vitro and in vivo. Inactivation of MLL1 leads to decreased expression of genes bound by NHA9 and MLL1 and reverses a gene expression signature found in NUP98-rearranged human leukemias. Our data reveal a molecular dependency on MLL1 function in NUP98-fusion-driven leukemogenesis.

Indexed as

AnimalsCell ProliferationChromatinGene Expression Regulation, NeoplasticHEK293 CellsHistone-Lysine N-MethyltransferaseHomeodomain ProteinsHumansLeukemiaMiceMyeloid-Lymphoid Leukemia ProteinNuclear Pore Complex ProteinsOncogene Proteins, FusionPromoter Regions, GeneticTumor Cells, CulturedChromatinHistone-Lysine N-MethyltransferaseHomeodomain ProteinsKmt2a protein, mouseMyeloid-Lymphoid Leukemia Proteinnuclear pore complex protein 98Nuclear Pore Complex ProteinsOncogene Proteins, FusionHox geneleukemiamixed lineage leukemia 1non-specific lethal histone-modifying complexesNUP98 fusion

Identifiers

PMID27889185
PMCPMC5501282
OpenAlexW2553171682

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.